1.Management of Clinical T1N0M0 Esophageal Cancer
Andrew J YANG ; Seo Hee CHOI ; Hwa Kyung BYUN ; Hyun Ju KIM ; Jinhyun CHOI ; Yong Chan LEE ; Sang Kil LEE ; Kyung Ran PARK ; Chang Geol LEE
Gut and Liver 2019;13(3):315-324
BACKGROUND/AIMS: Endoscopic resection is a standard treatment for stage T1a esophageal cancer, with esophagectomy or radical radiation therapy (RT) performed for stage T1b lesions. This study aimed to compare treatment outcomes of each modality for clinical stage T1 esophageal cancer. METHODS: In total, 179 patients with clinical T1N0M0-stage esophageal cancer treated from 2006 to 2016 were retrospectively evaluated. Sixty-two patients with clinical T1a-stage cancer underwent endoscopic resection. Among 117 patients with clinical T1b-stage cancer, 82 underwent esophagectomy, and 35 received chemoradiotherapy or RT. We compared overall survival (OS) and recurrence-free survival (RFS) rates for each treatment modality. RESULTS: The median follow-up time was 32 months (range, 1 to 120 months). The 5-year OS and RFS rates for patients with stage T1a cancer receiving endoscopic resection were 100% and 85%, respectively. For patients with stage T1b, the 5-year OS and RFS rates were 78% and 77%, respectively, for the esophagectomy group; 80% and 44%, respectively, for the RT alone group; and 96% and 80%, respectively, for the chemoradiation group. The esophagectomy group showed significantly higher RFS than the RT alone group (p=0.04). There was no significant difference in RFS between the esophagectomy and chemoradiation groups (p=0.922). Grade 4 or higher treatment-related complications occurred in four patients who underwent esophagectomy. CONCLUSIONS: Endoscopic resection appeared to be an adequate treatment for patients with T1a-stage esophageal cancer. The multidisciplinary approach involving chemoradiation was comparable to esophagectomy in terms of survival outcome without serious complications for T1b-stage esophageal cancer.
Chemoradiotherapy
;
Esophageal Neoplasms
;
Esophagectomy
;
Follow-Up Studies
;
Humans
;
Radiotherapy
;
Retrospective Studies
2.Origin of Osteoclasts: Osteoclast Precursor Cells
Jefferson TSAI ; Kaichi KANEKO ; Andrew J. SUH ; Richard BOCKMAN ; Kyung-Hyun PARK-MIN
Journal of Bone Metabolism 2023;30(2):127-140
Osteoclasts are multinucleated bone-resorbing cells and a key player in bone remodeling for health and disease. Since the discovery of osteoclasts in 1873, the structure and function of osteoclasts and the molecular and cellular mechanisms of osteoclastogenesis have been extensively studied. Moreover, it has been well established that osteoclasts are differentiated in vitro from myeloid cells such as bone marrow macrophages or monocytes. The concept showing that osteoclasts are derived from a specific population (named osteoclast precursor cells [OCPs]) among myeloid cells has been long hypothesized. However, the specific precursor population of osteoclasts is not clearly defined yet. A growing body of work provides evidence of the developmental origin and lifespan of murine osteoclasts, particularly in vivo. Here, we review the emerging evidence that supports the existence of OCPs and discuss current insights into their identity.
3.G2A Attenuates Propionibacterium acnes Induction of Inflammatory Cytokines in Human Monocytes.
Andrew J PARK ; George W AGAK ; Min QIN ; Lisa D HISAW ; Aslan PIROUZ ; Stephanie KAO ; Laura J MARINELLI ; Hermes J GARBÁN ; Diane THIBOUTOT ; Philip T LIU ; Jenny KIM
Annals of Dermatology 2017;29(6):688-698
BACKGROUND: Acne vulgaris is a disease of the pilosebaceous unit characterized by increased sebum production, hyperkeratinization, and immune responses to Propionibacterium acnes (PA). Here, we explore a possible mechanism by which a lipid receptor, G2A, regulates immune responses to a commensal bacterium. OBJECTIVE: To elucidate the inflammatory properties of G2A in monocytes in response to PA stimulation. Furthermore, our study sought to investigate pathways by which lipids modulate immune responses in response to PA. METHODS: Our studies focused on monocytes collected from human peripheral blood mononuclear cells, the monocytic cell line THP-1, and a lab strain of PA. Our studies involved the use of enzyme-linked immunosorbent, Western blot, reverse transcription polymerase chain reaction, small interfering RNA (siRNA), and microarray analysis of human acne lesions in the measurements of inflammatory markers. RESULTS: G2A gene expression is higher in acne lesions compared to normal skin and is inducible by the acne therapeutic, 13-cis-retinoic acid. In vitro, PA induces both the Toll-like receptor 2-dependent expression of G2A as well as the production of the G2A ligand, 9-hydroxyoctadecadienoic acid, from human monocytes. G2A gene knockdown through siRNA enhances PA stimulation of interleukin (IL)-6, IL-8, and IL-1β possibly through increased activation of the ERK1/2 MAP kinase and nuclear factor kappa B p65 pathways. CONCLUSION: G2A may play a role in quelling inflammatory cytokine response to PA, revealing G2A as a potential attenuator of inflammatory response in a disease associated with a commensal bacterium.
Acne Vulgaris
;
Blotting, Western
;
Cell Line
;
Cytokines*
;
Gene Expression
;
Gene Knockdown Techniques
;
Humans*
;
In Vitro Techniques
;
Interleukin-8
;
Interleukins
;
Isotretinoin
;
Microarray Analysis
;
Monocytes*
;
NF-kappa B
;
Phosphotransferases
;
Polymerase Chain Reaction
;
Propionibacterium acnes*
;
Propionibacterium*
;
Reverse Transcription
;
RNA, Small Interfering
;
Sebum
;
Skin
;
Toll-Like Receptors